Personalis Inc. (PSNL)
NASDAQ: PSNLHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PSNL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.71B
- EPS (TTM)
- -$1.09
- Dividend yield
- None
- 52-week range
- 4.96 – 18.89
- Day range
- 15.68 – 16.10
- Volume / Avg
- 3.82M / 3.60M
- Beta
- —
- Shares outstanding
- 106.80M
- Next earnings
- Nov 3, 2026
52-week range
PSNL stock today
On Oct 7, PSNL ended the session at $16.00, shedding $0.03 (0.19%), versus the S&P 500's 0.22% decline. Shares are 15.3% below their 52-week high of $18.89, set on Aug 21, 2026 and 222.9% above the 52-week low of $4.96, in the middle of the past year's range. PSNL is up 101.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 111.4%.
Personalis has posted a net loss over the last twelve months (EPS of -$1.09), so its P/E ratio is not meaningful. Personalis's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Personalis
Company profilePersonalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Christopher M. Hall
- Headquarters
- Fremont, CA
- Employees
- 259
- IPO year
- 2019
- Website
- personalis.com
Analyst forecast
ForecastConsensus (5 analysts)
hold
Avg. price target
$15.17-5.19%
- Strong buy 0
- Buy 1
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.26
Personalis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FRNMFreenome Inc. | 16.03 | -2.02% | $1.72B | vs PSNL |
| ALHCAlignment Healthcare Inc. | 8.55 | +2.15% | $1.77B | vs PSNL |
| FTREFortrea Holdings Inc. | 20.56 | -1.06% | $1.96B | vs PSNL |
| TRUPTrupanion Inc. | 24.63 | -0.20% | $1.07B | vs PSNL |
| LMRILumexa Imaging Holdings Inc. | 10.59 | -1.12% | $1.02B | vs PSNL |
| CSTLCastle Biosciences Inc. | 33.00 | -1.08% | $1.01B | vs PSNL |
| CLOVClover Health Investments Corp. Class A | 4.56 | -0.87% | $2.42B | vs PSNL |
| ACHCAcadia Healthcare Company Inc. | 29.23 | +0.65% | $2.72B | vs PSNL |
Indexes, lists and sector
Personalis stock FAQ
What is Personalis's stock price today?
PSNL last traded at $16.00 as of Oct 7, 4:00 PM EDT, down 0.19% on the day. Prices are delayed at least 15 minutes.
When is Personalis's next earnings date?
Personalis is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.26.
Who is Personalis's CEO?
Mr. Christopher M. Hall is the chief executive officer of Personalis Inc., which has about 259 employees.
What is the PSNL 52-week high?
The 52-week high for PSNL is $18.89 and the 52-week low is $4.96. The stock is currently 15.3% below its high.